肝癌治疗领域的新兴药物。
New agents on the horizon in hepatocellular carcinoma.
机构信息
Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, LH/POB 232, Boston, MA 02114, USA.
出版信息
Ther Adv Med Oncol. 2013 Jan;5(1):41-50. doi: 10.1177/1758834012458480.
Abstract
Despite the successful approval and extensive application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there have been renewed and continued interests and active research in developing other molecularly targeted agents in HCC during the past few years. While there is early evidence of antitumor activity of several agents in phase I/II studies, phase III efforts with a few targeted agents have failed, highlighting the challenges of new drug development in HCC. This review summarizes the current status of other molecularly targeted agents under development in advanced HCC.
摘要
尽管索拉非尼已成功获得批准并广泛应用，但晚期肝细胞癌（HCC）患者的预后仍然较差。幸运的是，在过去几年中，人们对开发其他 HCC 分子靶向药物重新产生了浓厚兴趣，并积极开展研究。虽然在 I/II 期研究中，有几种药物具有早期抗肿瘤活性的证据，但少数靶向药物的 III 期研究未能取得成功，突显了 HCC 新药开发的挑战。本文综述了晚期 HCC 中正在开发的其他分子靶向药物的现状。
相似文献
1
New agents on the horizon in hepatocellular carcinoma.
Ther Adv Med Oncol. 2013 Jan;5(1):41-50. doi: 10.1177/1758834012458480.
2
Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives.
Semin Oncol. 2012 Aug;39(4):493-502. doi: 10.1053/j.seminoncol.2012.05.014.
3
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.
World J Hepatol. 2015 Apr 18;7(5):787-98. doi: 10.4254/wjh.v7.i5.787.
4
New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.
Hepatol Res. 2015 Oct;45(10):E1-E11. doi: 10.1111/hepr.12459. Epub 2015 Jan 9.
5
Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.
N Am J Med Sci. 2011 Apr;3(4):167-75. doi: 10.4297/najms.2011.3167.
6
Emerging targeted strategies in advanced hepatocellular carcinoma.
Semin Liver Dis. 2013 Feb;33 Suppl 1:S11-9. doi: 10.1055/s-0033-1333632. Epub 2013 Mar 1.
7
Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Expert Opin Investig Drugs. 2010 May;19(5):663-72. doi: 10.1517/13543781003767426.
8
Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
Chin Clin Oncol. 2021 Feb;10(1):10. doi: 10.21037/cco-20-117. Epub 2020 May 14.
9
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
J Gastrointest Cancer. 2018 Jun;49(2):107-115. doi: 10.1007/s12029-018-0065-8.
10
Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.
World J Gastroenterol. 2012 Feb 14;18(6):498-506. doi: 10.3748/wjg.v18.i6.498.
引用本文的文献
1
Tubeimoside-2 Triggers Methuosis in Hepatocarcinoma Cells through the MKK4-p38α Axis.
Pharmaceutics. 2023 Mar 29;15(4):1093. doi: 10.3390/pharmaceutics15041093.
2
Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options.
J Clin Transl Hepatol. 2020 Jun 28;8(2):168-176. doi: 10.14218/JCTH.2020.00001. Epub 2020 Jun 10.
3
Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells.
Sci Rep. 2018 Jul 19;8(1):10923. doi: 10.1038/s41598-018-29199-8.
4
Pediatric hepatocellular carcinoma: challenges and solutions.
J Hepatocell Carcinoma. 2017 Jan 16;4:15-21. doi: 10.2147/JHC.S94008. eCollection 2017.
5
Hepatocellular Carcinoma: Current Questions and Future Directions.
Gastroenterol Hepatol (N Y). 2015 Mar;11(3):182-5.
6
Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.
Cancer Lett. 2016 Jan 1;370(1):78-84. doi: 10.1016/j.canlet.2015.09.020. Epub 2015 Oct 22.
7
Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.
World J Hepatol. 2015 Jun 18;7(11):1460-83. doi: 10.4254/wjh.v7.i11.1460.
8
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Oncologist. 2015 Jun;20(6):660-73. doi: 10.1634/theoncologist.2014-0465. Epub 2015 May 22.
9
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Oncologist. 2014 Nov;19(11):1169-78. doi: 10.1634/theoncologist.2014-0190. Epub 2014 Sep 15.
10
Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma.
J Hepatol. 2014 Nov;61(5):1064-72. doi: 10.1016/j.jhep.2014.05.027. Epub 2014 May 23.
本文引用的文献
1
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Clin Cancer Res. 2012 Apr 1;18(7):2090-8. doi: 10.1158/1078-0432.CCR-11-1991. Epub 2012 Jan 11.
2
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Clin Cancer Res. 2011 Nov 1;17(21):6914-23. doi: 10.1158/1078-0432.CCR-11-0793. Epub 2011 Aug 10.
3
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
Cancer. 2011 Nov 15;117(22):5094-102. doi: 10.1002/cncr.26165. Epub 2011 Apr 27.
4
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.
J Clin Oncol. 2011 Jun 10;29(17):2350-6. doi: 10.1200/JCO.2010.33.9432. Epub 2011 Apr 25.
5
Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.
Am J Clin Oncol. 2012 Aug;35(4):329-33. doi: 10.1097/COC.0b013e3182118cdf.
6
HCC and angiogenesis: possible targets and future directions.
Nat Rev Clin Oncol. 2011 May;8(5):292-301. doi: 10.1038/nrclinonc.2011.30. Epub 2011 Mar 8.
7
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Clin Cancer Res. 2011 Apr 1;17(7):1973-83. doi: 10.1158/1078-0432.CCR-10-2011. Epub 2011 Feb 24.
8
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
Cancer Chemother Pharmacol. 2011 Feb;67(2):315-24. doi: 10.1007/s00280-010-1320-2.
9
Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.
10
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.
Zotero 插件